Michael Devitt

University of Virginia Cancer Center

Biochemistry, Genetics and Molecular Biology · Life Sciences

10h-index516citations89works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chromatin Remodeling and Cancer(33), Bladder and Urothelial Cancer Treatments(19), Protein Degradation and Inhibitors(18), Cancer Mechanisms and Therapy(17), Cancer Immunotherapy and Biomarkers(16)

Publications89 total

Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP)
JCO Precision Oncology·2025· 1 cited
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes
Investigational New Drugs·2025· 1 citedOpen Access
MRI-Guided Adaptive Radiation Therapy for Oligometastatic Prostate Cancer Involving the Adrenal Gland: A Case Report and Literature Review
Case Reports in Oncology·2025Open Access
Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review
The Prostate·2025· 5 citedOpen Access
A single-institution experience of pneumonitis in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Journal of Clinical Oncology·2025
Impact of Renin-Angiotensin System Inhibitors on Response to PD1/L1 Inhibitors in Patients With Metastatic Renal Cell Carcinoma
Clinical Genitourinary Cancer·2024· 5 cited
Polo-Like Kinase-1 as a Potential Prognostic Marker of Prostate Cancer Utilizing ORIEN Data
Preprints.org·2024Open Access
When You Get to the Fork in the Road, Take It: The Challenges in Managing Patients With Advanced Prostate Cancer
JCO Oncology Practice·2024· 1 cited
Supplementary Figure S3 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Figure S5 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Table S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Materials and Methods from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Figure S1 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Figure S1 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Figure S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Data from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Figure S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Figure S6 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Table S2 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Figure S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
page 1 of 5Next →

Frequent Co-authors

Ali Raza Khaki(11), Petros Grivas(11), Leonidas Nikolaos Diamantopoulos(10), Rafael Morales‐Barrera(10), Ariel Ann Nelson(10), Monika Joshi(10), Guru Sonpavde(10), Mehmet Asım Bilen(9), Christopher Hoimes(9), David J. Pinato(9), Sandy Liu(9), Jure Murgić(9), Abhishek Tripathi(9), Evan Y. Yu(9), Benjamin A. Gartrell(8), Alex Sankin(8), Alejo Rodríguez‐Vida(8), Alexandra Drakaki(8), Lucía Alonso Buznego(8), Ignacio Durán(8)